Shares of Faron Pharmaceuticals Oy (LON:FARN) were down 12.3% on Thursday . The stock traded as low as GBX 66.50 ($0.87) and last traded at GBX 67.55 ($0.88). Approximately 330,615 shares changed hands during mid-day trading, an increase of 2,180% from the average daily volume of 14,501 shares. The stock had previously closed at GBX 77 ($1.01).

COPYRIGHT VIOLATION NOTICE: “Faron Pharmaceuticals Oy (FARN) Stock Price Down 12.3%” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at

About Faron Pharmaceuticals Oy (LON:FARN)

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute organ traumas, vascular damage, and cancer immunotherapy. The company's lead product candidate is Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS).

Recommended Story: What is the Dividend Aristocrat Index?

Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with's FREE daily email newsletter.